



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

Date: 22/02/2025

To,

National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (E)
Mumbai - 400051

Subject: Format of Integrated filing (financial) for the quarter ended December 31, 2024

SYMBOL: AJOONI

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter ended December 31, 2024.

- a. Financial Results (Enclosed as **Annexure 1**)
- b. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc. (Enclosed as **Annexure 2**)
- c. Format for Disclosing outstanding default on Loans and Debt Securities (Enclosed as **Annexure 3**)
- d. Format for Disclosure of Related Party Transactions (**Not applicable for the period ended December 31,2024**)
- e. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along-With Annual Audited Financial Results (**Not applicable for the period ended December 31,2024**)

Thanking You,

Yours Truly,

For AJOONI BIOTECH LIMITED

Jasjot Singh
Managing Director
DIN: 01937631

AJOONI BIOTECH LIMITED
CIN : L85190PB2010PLC040162

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2024 (In Lakhs)

PARTICULARS	QUARTER ENDED					Year Ended (Audited)
	31.12.2024	30.09.2024	31.12.2023	Period Ended (UnAudited)	Period Ended (UnAudited)	31.03.2024
				31.12.2024	31.12.2023	
I Income						
Revenue from operations	3,403.46	2,572.44	2,005.04	8,541.75	6,053.30	8,011.46
Other income	38.63	30.96	157.43	73.26	193.65	219.33
Total income from operations	3,442.09	2,603.40	2,162.47	8,615.01	6,246.95	8,230.79
II Expenses						
Cost of Material Consumed	2,924.11	2,247.25	1,813.35	7,456.33	5,459.95	6,986.34
Change In Inventories	(24.21)	9.41	29.82	(23.52)	26.64	48.65
Employee benefit expenses	89.13	70.31	61.40	216.72	166.11	180.05
Finance costs	6.83	5.90	12.08	27.75	44.65	55.69
Depreciation and amortization expenses	23.75	22.56	21.34	71.25	63.59	87.42
Payment to NSE						
Other expenses	321.50	168.50	166.21	624.74	336.23	573.03
Total expenses	3,341.11	2,523.93	2,104.20	8,373.27	6,097.17	7,931.18
III Profit/(Loss) before exceptional items and tax	100.98	79.47	58.27	241.74	149.78	299.61
IV Exceptional items						
V Profit/(Loss) before tax	100.98	79.47	58.27	241.74	149.78	299.61
VI Tax expenses						
a) Current tax	22.22	19.07	15.14	53.18	27.64	87.50
b) Deferred tax	5.74	-1.11362298	(0.85)	5.74	(2.50)	4.01
b) Mat Credit						
VII Net Profit/(Loss) for the period/year	73.02	61.51	43.98	182.82	124.64	208.10
VIII Other comprehensive income (net of tax)						
loss:	2.14	54.14	-	56.28	(162.77)	(103.22)
Total other comprehensive income						
IX Total comprehensive income for the period/year (VII+VIII)	75.16	115.65	43.98	239.10	(38.13)	112.09
X Paid-up equity share capital (face value of the share shall be indicated)	3,444.87	3,444.87	1,752.27	3,444.87	1,752.27	1,752.27
XI Other equity (excluding revaluation reserve)	5,288.88	5,167.57	2,361.76	5,288.88	2,361.76	2,518.51

7704



XII	EPS in Rs. (Face Value of Rs.2/- each)*				-		
	-Basic	0.04	0.04	0.25	0.07	0.71	0.25
	-Diluted	0.04	0.04	0.25	0.07	0.71	0.25

Notes:


1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 13.02.2025 after being reviewed by the Audit Committee.
2. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.
3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

Place : Mohali
Date : 13.02.2025

For Ajooni Biotech Limited

→→→→

Jasjot Singh
Managing Director
DIN: 01937631





AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)

Corporate Office : H.No. 1769, Phase 3B2, Mohali-160059

Phone : 0172-5020758-69 Website : www.ajoonibiotech.com

E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

AJOONI BIOTECH LIMITED


CIN : L85190PB2010PLC040162

Statement of Assets and Liabilities

For the Year ended on 31st december 2024

in Rs. (Lakhs)

PARTICULARS	31st december 2024	31ST MARCH 2024
I. ASSETS		
(1) Non - Current Assets		
a) Property, Plant and Equipment	1,146.86	1,031.89
b) Capital Work In Progress	0.00	92.45
c) Investment Property		-
d) Goodwill		-
e) Other Intangible Assets		-
f) Intangible Assets Under Development		-
g) Biological Assets other than Bearer Plants		-
h) Financial Assets		
(1) Investments	437.36	213.63
(2) Trade Receivables		-
(3) Loans		-
(4) Other Financial Assets		
i) Deferred Tax Asset (net)	36.96	31.22
j) Other Non Current Asset	240.11	150.00
(2) Current Assets		
a) Inventories	2,089.27	1,536.73
b) Financial Assets		
(1) Investments		
(2) Trade Receivables	2,179.63	1,295.94
(3) Cash & Cash Equivalent	1,759.22	42.82
(4) Bank Balances other than (iii) above		
(5) Loans and Advances	1,458.61	351.42
(6) Other Financial Asset		0.00



c) Current Tax Assets (net)		-
d) Other Current Asset	18.92	5.93
TOTAL	9,366.94	4,752.04
II EQUITY AND LIABILITIES		
(1) Equity		
a) Equity Share Capital	3,444.87	1,752.27
b) Other Equity	5,288.88	2,518.51
(2) Non-Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	206.15	168.20
(2) Trade Payables		
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	13.04	11.99
c) Deferred Tax Liability (net)		-
d) Other Non Current Liability		-
(3) Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	0.00	48.57
(2) Trade Payables	295.85	158.45
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	1.48	1.05
c) Other Current Liabilities	63.49	5.48
d) Current tax liabilities (Net)	53.18	87.50
TOTAL	9,366.94	4,752.04

Place : Mohali
Date : 13.02.2025

For Ajooni Biotech Limited

Jasjot Singh
Managing Director
DIN: 01937631





NARINDER KUMAR & COMPANY
CHARTERED ACCOUNTANTS

SCO 65-B (1st Floor) City Heart,
Kharar Chandigarh Road,
Kharar, SAS Nagar Mohali-140301
Mobile : 98154 50065
Email : nkgargca@yahoo.co.in

Ref. No. **Limited Review Report** dated

Review Report to Board of Directors of M/s Ajooni Biotech Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Ajooni Biotech Limited having Regd. office at D-118, Industrial Area, Phase-VII, Mohali Punjab-160055. for the period ended 31st December, 2024,(the Statement) attached herewith , being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations 2015 (as amended) , Including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to Time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NARINDER KUMAR AND COMPANY
Chartered Accountants



Narinder Kumar Garg
(NARINDER KUMAR GARG)

PARTNER
M.NO-080287

Date:- 13.02.2025
UDIN:- 25080287BMLIQF1154



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

STATEMENT OF DEVIATION OR VARIATION IN UTILIZATION OF FUNDS RAISED

Name of Listed Entity	Ajooni Biotech Limited					
Mode of Fund Raising	Right Issue					
Date of Raising Funds	06.06.2024 (Date of Allotment)					
Amount raised	Rs. 42,31,49,385/-					
Report filed for Quarter ended	31.12.2024					
Monitoring Agency	-					
Monitoring Agency Name, if applicable	-					
Is there a Deviation/Variation in use of fund raised	No					
If Yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the Unit Holders	-					
If Yes, Date off Unit holders Approvals	-					
Explanation for the Deviation/Variation	-					
Comments of the Audit Committee after review	-					
Comments of the auditors, if any						
Set forth below are objects for which funds have been raised in the Right Issue and details of Deviation, if any, in the following Table:						
Original Object	Modified Object, if any	Original Allocation (Rs. In lakhs)	Modified Allocation, if any	Funds utilised (Rs. In lakhs)	Amount of Deviation/Variation for Quarter according to applicable object	Remarks, if any
To Finance Expenditure towards Acquisition of Land, Site Development and Other Civil Work.	NA	806.60	779.02	433.34	0.00	NA
To Acquire	NA	875.00	845.30	67.6	0.00	NA



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

the Plant & Machinery						
To part finance the working capital requirement	NA	1,600.00	1545.34	1545.34	0.00	NA
To meet General corporate purposes.	NA	1,050.00	1014.30	500.71	0.00	NA
To meet the expenses of the Issue	NA	49.09	47.40	46.21	0.00	NA
TOTAL		4,380.69	4231.49	2593.19	0.00	

Note: Rs. 1638.17 lakhs is un-utilised/ bank balance.

Deviation or Variation could mean:

- Deviation in the objects or purposes for which the funds have been raised or
- Deviation in the amount of Funds actually utilized as against what was originally disclosed or
- Change in terms of a contract referred to in the fund raising document i.e letter of Offer.

For AJOONI BIOTECH LIMITED

Jasjot Singh
Managing Director
DIN: 01937631



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Corp Office: H.No 1769, Phase 3B2, Mohali-160059

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

Annexure 3

FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES

S. No.	Particulars	Amount (In Rs. Lakhs)
1.	Loans / revolving facilities like cash credit from banks / financial institutions	
A	Total amount outstanding as on date	206.15
B	Of the total amount outstanding, amount of default as on date	Nil
2.	Unlisted debt securities i.e. NCDs and NCRPS	
A	Total amount outstanding as on date	0.0
B	Of the total amount outstanding, amount of default as on date	0.0
3.	Total financial indebtedness of the listed entity including short-term and long-term debt	206.15